Hereditary amyloidosis is a genetic disorder involving abnormal protein deposits affecting various organs. The two main types are Non-ATTR and ATTR, each with distinct causes and treatments. Management includes symptom relief and therapies to reduce amyloid buildup. Ongoing research offers hope for more effective solutions. Always seek medical advice for diagnosis and treatment options.

Exploring the Main Types of Hereditary Amyloidosis and Their Impact

Hereditary amyloidosis is a genetic disorder characterized by abnormal amyloid protein buildup in tissues and organs. These misfolded proteins can cause significant damage over time, with symptoms typically manifesting in adulthood. The two primary forms are:

Non-ATTR: A rarer form caused by mutations in proteins such as Apolipoprotein AI, Fibrinogen Aa, and Lysozyme, often leading to kidney failure.

ATTR: Resulting from mutations in the TTR gene, producing unstable transthyretin proteins that deposit in organs and nerves, making it the most common hereditary amyloidosis type.

Treatment Approaches: The goal is to manage symptoms and slow disease progression. Supportive treatments help with nerve, cardiac, and kidney complications, alleviating pain and autonomic issues. Disease-specific therapies focus on decreasing amyloid production, including liver transplants and new drugs targeting TTR. Research continues with clinical trials exploring innovative management options.

Important Note: This information is for educational purposes and does not replace professional medical advice. Consult healthcare professionals for diagnosis and treatment planning.